期刊
FRONTIERS IN ONCOLOGY
卷 9, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2019.01187
关键词
YY1; angiogenesis; vascular endothelial growth factor A; transcription activation; hepatocellular carcinoma
类别
资金
- National Natural Science Funds of China [81572838, 81872374, 81703581, 81871972, 81902441]
- Tianjin Science and Technology Project [18PTSYJC00060]
- Chinese National Major Scientific and Technological Special Project for Significant New Drugs Development [2018ZX09736005, SQ2018ZX090201]
- National Key Research and Development Program of China [2018YFA0507203]
- Postdoctoral support scheme for innovative talents [BX20180150]
- China Postdoctoral Science Foundation [2018M640228]
- Fundamental Research Funds for the Central Universities, Nankai University
Hepatocellular carcinoma (HCC) is a typical hypervascular solid tumor that requires neoangiogenesis for growth. The vascular endothelial growth factor (VEGF) is the most potent proangiogenic factor in neovascularization. The multifunctional Yin-Yang 1 (YY1) is involved in the regulation of tumor malignancy of HCC. However, the relationship between YY1 and endothelial cell-dependent tumor angiogenesis in HCC remains unclear. In this study, we observed that YY1 is positively correlated with microvessel density (MVD) and poor prognosis in HCC tissues. We further found that YY1 promotes the transcriptional activity of VEGFA by binding its promoter in HCC. The secreted VEGFA from HCC cells activates phosphorylation of VEGFR2 to promotes tube formation, cell migration, and invasion of vascular endothelial cells in vitro, and promotes tumor growth and angiogenesis in vivo. In addition, upregulation of YY1 enhanced resistance of bevacizumab in HCC cells. These results indicate that YY1 plays essential roles in HCC angiogenesis and resistance of bevacizumab by inducing VEGFA transcription and that YY1 may represent a potential molecular target for antiangiogenic therapy during HCC progression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据